Option chain shows key data for Peijia Medical's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Peijia Medical.

Peijia Medical (OTC:PEJMF) Stock, Option Chain

Peijia Medical Ltd is focused on the interventional procedural, transcatheter valve therapeutic, and the neurointerventional procedural medical device market in China. The company's product candidates include Transcatheter Aortic Valve Replacement products, Transcatheter Mitral Valve Replacement/Transcatheter Tricuspid Valve Replacement products, Ancillary products, Neurointerventional products, and its product pipeline consists of transcatheter valve therapeutic and neurointerventional products and product candidates. Its operating segments are Transcatheter Valve Therapeutic Business and Neurointerventional Business.

Peijia Medical Ltd

Telsey Advisory Group analyst Dana Telsey maintains a.k.a. Brands Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKA#NYSE">AKA</a>) with a Market Perform and maintains $22 price target.

News

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Market Perform on a.k.a. Brands Holding, Maintains $22 Price Target

Telsey Advisory Group analyst Dana Telsey maintains Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) with a Outperform and maintains $43 price target.

BBWI

Telsey Advisory Group Maintains Outperform on Bath & Body Works, Maintains $43 Price Target

Financial Outlook
Docebo is providing financial guidance for the fiscal year ending December 31, 2025 as follows:
<ul>
<li>Subscription revenue growth of 11.5% to 12.5% or 13.0% to 14.0% after adjusting for negative impact of 1.5% resulting from the strengthening of the U.S. dollar relative to foreign currencies</li>
<li>Total revenue growth between 11.0% and 12.0% or 12.5% to 13.5% after adjusting for negative impact of 1.5% resulting from the strengthening of the U.S. dollar relative to foreign currencies</li>
<li>Adjusted EBITDA as a percentage of total revenue between 18.0% and 19.0%</li>
</ul>

Guidance

DCBO

Docebo Expects FY25 Revenue Growth Of 11.0%-12.0% Vs $246.22M Est And Adj Revenue Growth Of 12.5%-13.5%

<ul>
<li>With 10.0 GW of signed PPAs in 2023 and 2024, on track to achieve target of signing 14 to 17 GW in 2023 to 2025.</li>
<li>Expecting to complete construction of 3.2 GW of new renewables in 2025.</li>
</ul>

AES Initiates 2025 Guidance For Adjusted EBITDA Of $2.65B - $2.85B; Reaffirms Annualized Growth Target Of 5% To 7% Through 2027, Off Base Of 2023 Guidance

&nbsp;
Docebo is providing financial guidance for the three months ended March 31, 2025 as follows:
<ul>
<li>Total revenue between $57.0 million and $57.2 million which includes an approximately 1.5% negative impact resulting from the strengthening of the U.S. dollar relative to foreign currencies</li>
<li>Adjusted EBITDA as a percentage of total revenue between 14.5% to 15.0%</li>
</ul>

Docebo Expects Q1 Revenue Of $57.0M-$57.2M Vs $58.43M Est

Telsey Advisory Group analyst Sarang Vora maintains Vital Farms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VITL#NASDAQ">VITL</a>) with a Outperform and maintains $52 price target.

VITL

Telsey Advisory Group Maintains Outperform on Vital Farms, Maintains $52 Price Target

General

NextDecade Says Overall Project Completion Percentage For Trains 1 And 2 And The Common Facilities Of The Rio Grande LNG Facility Was 38.1%

Earnings

Earnings Beats

Docebo Q4 2024 Adj. EPS $0.28 Beats $0.16 Estimate, Sales $57.041M Beat $56.211M Estimate

Telsey Advisory Group analyst Joseph Feldman maintains Traeger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COOK#NYSE">COOK</a>) with a Outperform and maintains $4 price target.

COOK

Telsey Advisory Group Maintains Outperform on Traeger, Maintains $4 Price Target

NW Natural Holdings reaffirmed its long-term EPS growth rate target of 4% to 6% compounded annually from the expected 2025 adjusted EPS3.
We expect NW Natural Holdings capital expenditures for 2025 to be in the range of $450 - $500 million including:
<ul>
<li>NW Natural Gas Company capital expenditures of $330 - $360 million,</li>
<li>SiEnergy capital expenditures of $65 - $75 million, and</li>
<li>NW Natural Water capital expenditures of $55 - $65 million.</li>
</ul>

Northwest Natural Gas Sees FY25 Adjusted EPS Of $2.75-$2.95 Vs $2.88 Est.

Reaffirming annualized growth target of 7% to 9% through 2025, off a base of 2020 and 7% to 9% through 2027, off a base of 2023 guidance

AES Initiates 2025 Guidance For Adjusted EPS Of $2.10 - $2.26

Telsey Advisory Group analyst Dana Telsey maintains FIGS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIGS#NYSE">FIGS</a>) with a Market Perform and maintains $7 price target.

FIGS

Telsey Advisory Group Maintains Market Perform on FIGS, Maintains $7 Price Target

AES (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate of $0.34 by 58.82 percent. This is a 26.03 percent decrease over earnings of $0.73 per share from the same period last year. The company reported quarterly sales of $2.96 billion which missed the analyst consensus estimate of $3.07 billion by 3.54 percent. This is a 0.20 percent decrease over sales of $2.97 billion the same period last year.

Earnings Misses

AES Q4 2024 Adj EPS $0.54 Beats $0.34 Estimate, Sales $2.96B Miss $3.07B Estimate

2025 Financial Guidance
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Full Year 2025 Guidance</td>
<td colspan="1" rowspan="1">Full Year 2024 Actuals</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net revenue</td>
<td colspan="1" rowspan="1">$3.0 billion - $3.1 billion</td>
<td colspan="1" rowspan="1">$2.79 billion</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA (1)</td>
<td colspan="1" rowspan="1">$650 million - $675 million</td>
<td colspan="1" rowspan="1">$627 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted diluted EPS (2)</td>
<td colspan="1" rowspan="1">$0.65 - $0.70</td>
<td colspan="1" rowspan="1">$0.58</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating cash flow</td>
<td colspan="1" rowspan="1">$255 million - $285 million</td>
<td colspan="1" rowspan="1">$295 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating cash flow, excluding discrete items (3)</td>
<td colspan="1" rowspan="1">$280 million - $310 million</td>
<td colspan="1" rowspan="1">$348 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Capital expenditures (4)</td>
<td colspan="1" rowspan="1">Approximately $100 million</td>
<td colspan="1" rowspan="1">$52 million</td>
</tr>
</tbody>
</table>
</figure>

Health Care

AMRX

Amneal Expects 2025 Revenues Of $3B-$3.1B And Adjusted EPS Of $0.65-$0.70 Versus Consensus Of $2.896B And $0.71, Respectively

Northwest Natural Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NWN#NYSE">NWN</a>) reported quarterly earnings of $1.41 per share which beat the analyst consensus estimate of $1.37 by 2.92 percent. The company reported quarterly sales of $370.88 million which missed the analyst consensus estimate of $395.05 million by 6.12 percent. This is a 4.26 percent increase over sales of $355.71 million the same period last year.

Northwest Natural Hldg Q4 2024 Adj EPS $1.41 Beats $1.37 Estimate, Sales $370.88M Miss $395.05M Estimate

Amneal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRX#NASDAQ">AMRX</a>) reported quarterly earnings of $0.12 per share which missed the analyst consensus estimate of $0.15 by 20 percent. This is a 14.29 percent decrease over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $730.52 million which beat the analyst consensus estimate of $707.55 million by 3.25 percent. This is a 18.40 percent increase over sales of $616.98 million the same period last year.

Amneal Pharmaceuticals Q4 2024 Adj EPS $0.12 Misses $0.15 Estimate, Sales $730.52M Beat $707.55M Estimate

Intl Cons Airlines Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ICAGY#OTC">ICAGY</a>) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.17 by 64.71 percent. This is a 33.33 percent increase over earnings of $0.21 per share from the same period last year. The company reported quarterly sales of $8.59 billion which beat the analyst consensus estimate of $7.65 billion by 12.30 percent. This is a 10.44 percent increase over sales of $7.78 billion the same period last year.

Internationalnsolidated Airlines Group Sponsored American Depository Receipt

ICAGY

Intl Cons Airlines Group Q4 Adj EPS $0.28 Beats $0.17 Estimate, Sales $8.59B Beat $7.65B Estimate

U.S. stock futures rose on Friday following Thursday&#8217;s sell-off. Futures of all benchmark indices advanced in premarket trading, except the small-cap gauge Russell 2000.
Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) fell over 8% on Thursday, dragging the tech-heavy Nasdaq 100 down despite the strong quarter as its gross margins fell sequentially, caused by the ramp-up in the production of its Blackwell chips.
Meanwhile, President Donald Trump escalated tariff threats against Mexico and Canada, saying that it will go into effect as scheduled on March 4, in a social media post. He further threatened additional tariffs on China, following his pledge to impose 25% tariffs on the EU.
Investors await Friday&#8217;s personal consumption expenditure inflation data amid uncertainty over interest rate cuts as it is the Federal Reserve&#8217;s preferred inflation gauge.
The 10-year Treasury yield stood at 4.25%, while the two-year yield was at 4.05%. According <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">to</a> the CME Group's FedWatch tool, there is a 94.5% chance that the Federal Reserve will keep interest rates unchanged for the March meeting.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.27%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.30%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.27%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.06%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Friday. SPY was up 0.35% to $587.09, and QQQ advanced 0.28% to $501.67, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
Most sectors in the S&amp;P 500 ended lower Thursday, with technology and communication services leading the decline. However, financial and energy stocks bucked the trend.
The Nasdaq Composite dropped over 500 points, dragged down by Nvidia&#8217;s 8% plunge after its Q4 earnings.
Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) declined after missing revenue estimates, whereas, SoundHound AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) rose in after-hours after beating analyst expectations. Rocket Lab USA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) shares dropped after a weak first-quarter guidance.
Economic data showed a slight upward revision to fourth quarter GDP according to its second reading released on Thursday. Also, initial jobless claims rose by 22,000 from the previous week to 242,000, the most in over two months and above market expectations of 221,000.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-2.78%</td>
<td>18,544.42</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-1.59%</td>
<td>5,861.57</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.45%</td>
<td>43,239.50 </td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.59%</td>
<td>2,139.66</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
Ryan Detrick, the chief market strategist at Carson Research highlighted that the first quarter of a post-election year tends to be &#8220;quite weak&#8221;. &#8220;This choppy start to 2025 isn&#8217;t abnormal. Don&#8217;t panic,&#8221; he added.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">As we&#39;ve noted many times, the first quarter of a post-election year tends to be quite weak. This choppy start to 2025 isn&#39;t abnormal. Don&#39;t panic. <a href="https://t.co/5tQjYeqd6G">pic.twitter.com/5tQjYeqd6G</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1895314476557312425?ref_src=twsrc%5Etfw">February 28, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
He also continued reiterating his February seasonality stance via his X posts. He highlighted that junk corporate bonds, also called high-yield bonds, were up the past five days as the S&amp;P 500 was down over 4%.
&#8220;If the end was near like they keep telling us this wouldn&#8217;t be the case. Remain calm, this is simply seasonal late February shenanigans,&#8221; he said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The S&amp;P 500 is down 4% the past five days. High yield bonds are UP the past five days. If the end was near like they keep telling us this wouldn&#39;t be the case. Remain calm, this is simply seasonal late February shenanigans. <a href="https://t.co/FF2TtFJGz5">pic.twitter.com/FF2TtFJGz5</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1895318792634606066?ref_src=twsrc%5Etfw">February 28, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Furthermore, he dismissed the validity of price-to-earnings ratio, saying that there was no &#8220;correlation between P/E multiples and what stocks will do a year later.&#8221;
George Smith, portfolio strategist at LPL Financial highlighted his take on investor sentiment by analyzing survey data from the American Association of Individual Investors and Bank of America Global Fund Manager Survey.
AAII&#8217;s latest sentiment survey reveals significantly bearish sentiment among individual investors for the fourth consecutive week, with the bull-bear spread at a 10-year high. This extreme bearishness, viewed through a contrarian lens, could be a positive signal for stocks, said Smith.
However, the BofA Global Fund Manager Survey presents a more mixed picture, with professional investors cautiously optimistic about the economy but concerned about overvalued U.S. equities. Overall, these surveys suggest a relatively neutral market outlook, aligning with LPL Research&#8217;s neutral stance on equities due to a balance of positive and negative factors, explained Smith.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep on Friday:
<ul>
<li>January's personal income, spending, core and headline PCE index, advanced U.S. trade balance in goods, retail and wholesale inventories will be out by 8:30 a.m., ET.</li>
</ul>
<ul>
<li>Richmond Fed President Tom Barkin will speak at 8:30 a.m., ET as well.</li>
</ul>
<ul>
<li>February's Chicago business barometer data will be released at 9:45 a.m., ET.</li>
</ul>
<ul>
<li>Chicago Fed President Austan Goolsbee will speak at 10:15 p.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Owens &amp; Minor Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) rose 0.78% in the premarket on Friday ahead of its earnings, which will be released before the opening bell. Analysts expect it to report earnings of 52 cents per share on the revenue of $2.69 billion.</li>
</ul>
<ul>
<li>Chart Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>) declined 0.14% as Wall Street expects it to report quarterly earnings of $3.15 per share on revenue of $1.17 billion before the opening bell.</li>
</ul>
<ul>
<li>Integral Ad Science Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAS#NASDAQ">IAS</a>) fell 1.55% ahead of its earnings, which will be released before the opening bell. Analysts expect it to report earnings of 25 cents per share on the revenue of $148.83 million.</li>
</ul>
<ul>
<li>HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) was 3.41% lower despite meeting EPS and revenue estimates as it guided for lower than expected second-quarter adjusted EPS between 75 to 85 cents.</li>
</ul>
<ul>
<li>Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) dropped 2.06% as it missed the revenue expectations amid a mixed quarter.</li>
</ul>
<ul>
<li>SoundHound AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) jumped 5.86% after posting a strong quarter and issuing a positive guidance for the next fiscal year.</li>
</ul>
<ul>
<li>Rocket Lab USA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) slumped 10.99% as it reported a weaker than expected first quarter guidance.</li>
</ul>
<ul>
<li>Rapid Micro Biosystems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPID#NASDAQ">RPID</a>) climbed 40.48% as it signed a 5-year global distribution deal with MilliporeSigma.</li>
</ul>
<ul>
<li>Virpax Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) surged 39.04% as it reported positive human study results for its Molecular Envelope Technology, a key component in its Envelta and NobrXiol products, with no moderate to severe adverse events.</li>
</ul>
<ul>
<li>Powell Max Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMAX#NASDAQ">PMAX</a>) zoomed 77.05% as it announced that it will acquire Miracle Media Production from Vision Access Enterprises and M Digital Partners Company. The acquisition is expected to enhance Powell Max&#8217;s services and create synergies.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 1.11% to hover around $69.57 per barrel.
The gold spot index was down by 0.53% to $2,861.73 per ounce. Its last record high was at $2,956.37. The Dollar Index was up 0.12% at the 107.373 level.
Asian markets fell on Friday, including Japan's Nikkei 225, China's CSI 300, Australia's ASX 200, India's S&amp;P BSE Sensex, South Korea's Kospi, and Hong Kong's Hang Seng index. European markets were also mostly lower in trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/44035798/dell-technologies-projects-15-billion-ai-server-revenue-for-fy26-raises-dividend-18-amid-a-mixed-quarter">Dell Technologies Projects $15 Billion AI Server Revenue For FY26, Raises Dividend By 18% Amid A Mixed Quarter</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Government

Market Summary

Futures

Treasuries

Economics

Pre-Market Outlook

Markets

DELL

GTLS

NVDA

PMAX

RKLB

RPID

SOUN

VRPX

US Stocks Likely To Open Higher Following A Sell-Off, 'This Choppy Start To 2025 Isn't Abnormal. Don't Panic,' Says Expert Highlighting Seasonal Weakness In The First Quarter After Elections

Telsey Advisory Group analyst Dana Telsey maintains Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) with a Market Perform and maintains $26 price target.

Telsey Advisory Group Maintains Market Perform on Gap, Maintains $26 Price Target

Telsey Advisory Group analyst Dana Telsey maintains J.Jill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JILL#NYSE">JILL</a>) with a Market Perform and maintains $31 price target.

Comments

Peijia Medical

Peijia Medical (PEJMF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga